Twenty-two patients with elevated prostate-specific antigen and biopsy-proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with androgen deprivation, radiation therapy, or both, and a Gleason-matched control group who had not received such therapy.
“Diffusion t ensor MR tractography may function as a novel quantitative tool and marker of treatment response,” said study coauthor Jennifer W. Uyeda, MD, Brigham and Women’s Hospital. “For example, absence of rise in tract density after therapy and persistent or wider gradient can signify poor response.”
The study was presented at the ARRS 2015 Annual Meeting in Toronto.
Founded in 1900, ARRS is the first and oldest radiology society in the United States, and is an international forum for progress in radiology. The Society’s mission is to improve health through a community committed to advancing knowledge and skills in radiology. ARRS achieves its mission through an annual scientific and educational meeting, publication of the American Journal of Roentgenology (AJR) and InPractice magazine, topical symposia and webinars, and print and online educational materials. ARRS is located in Leesburg, VA.